Collaboration and License Agreements - ModernaTX, Inc - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended | ||||
---|---|---|---|---|---|
Jan. 31, 2023 |
Jun. 30, 2023 |
Dec. 31, 2022 |
Jun. 30, 2022 |
Dec. 31, 2021 |
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Deferred revenue | $ 261,153 | $ 301,326 | $ 264,895 | $ 284,760 | |
ModernaTX, Inc | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Deferred revenue | 32,300 | ||||
ModernaTX, Inc | Collaboration and License Agreement | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Upfront payment received | $ 35,000 | ||||
Up front consideration pre paid research and development service fees | 5,000 | ||||
Deferred revenue | 32,300 | 35,000 | |||
Amount due from customer | $ 0 | $ 35,000 | |||
ModernaTX, Inc | Collaboration and License Agreement | Maximum | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Contingent milestone payments receivable | $ 1,200,000 |